Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Patients must have advanced (unresectable or metastatic) biopsy-proven pancreatic NET~2. Measurable disease by radiologic assessment~3. Adequate blood work~4. Performance Status 0-2 : Ability to be out of bed most of the time~5. Adult male or female patients ≥ 18 years of age~6. Women of childbearing potential must have a negative serum pregnancy test~7. Written informed consent from patients must be obtained in accordance to local guidelines~Exclusion criteria:~1. Patients with severe kind of (poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma) cancer are not eligible~2. Other chemotherapy, immunotherapy or radiotherapy within 4 weeks prior to starting this trial~3. Hepatic artery procedure called embolization within the last 6 months (1 month if there are other sites of measurable disease), or cryoablation/ radiofrequency ablation of hepatic metastasis within 2 months of enrollment~4. Prior therapy with the same kind of medication (mTOR inhibitors: sirolimus, temsirolimus, everolimus).~5. Uncontrolled diabetes mellitus Patients who have any severe and/or uncontrolled medical conditions such as:~6. Patients receiving chronic treatment with corticosteroids or another immunosuppressive agent~7. Patients with a known history of HIV seropositivity~8. No other prior or concurrent cancer at the time enrolling to this trial~Other protocol defined inclusion/ exclusion criteria applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Everolimus 10 mg/day (Type: EXPERIMENTAL): Participants received 10 mg per day of Everolimus plus best supportive care. Patients received their first dose of everolimus at Visit 2 (Cycle 1 Day 1).
- Placebo (Type: PLACEBO_COMPARATOR): Participants received matching placebo to everolimus daily plus best supportive care. Patients received their first dose of matching placebo at Visit 2 (Cycle 1 Day 1).

Based on this trial design, predict the completion outcome and termination type (if applicable).